Company News-Gan & Lee

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2024 2023 2022 2021 2018

Gan & Lee Pharmaceuticals Begins First In-Human Trial in China for Investigational Compound, GZR18
Gan & Lee 2021-12-10
Gan & Lee Pharmaceuticals Announces NMPA Acceptance of Investigational New Drug (IND) for Once-Weekly Insulin GZR4
Gan & Lee 2021-11-30
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
Gan & Lee 2021-10-14
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
Gan & Lee 2021-09-09
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association’s 81st Scientific Sessions
Gan & Lee 2021-07-02
Mixed Protamine Human Insulin Injection (30R) from Gan & Lee Pharmaceuticals Approved for Listing in China
Gan & Lee 2021-05-04

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe